ANI Pharmaceuticals Return On Asset vs. Cash And Equivalents
| ANIP Stock | USD 57.23 2.16 3.64% |
For ANI Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ANI Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ANI Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ANI Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ANI Pharmaceuticals over time as well as its relative position and ranking within its peers.
ANI |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 13.824 | Earnings Share (0.47) | Revenue Per Share 28.915 | Quarterly Revenue Growth 0.125 | Return On Assets 0.0125 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ANI Pharmaceuticals Cash And Equivalents vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ANI Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare ANI Pharmaceuticals value to that of its competitors to determine the firm's financial worth. ANI Pharmaceuticals is rated second in return on asset category among its peers. It is rated below average in cash and equivalents category among its peers creating about 5,070,400,000 of Cash And Equivalents per Return On Asset. Comparative valuation analysis is a catch-all technique that is used if you cannot value ANI Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ANI Cash And Equivalents vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
ANI Pharmaceuticals |
| = | 0.0125 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
ANI Pharmaceuticals |
| = | 63.38 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
ANI Cash And Equivalents Comparison
ANI Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
ANI Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ANI Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ANI Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of ANI Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of ANI Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 8.9 M | 9.3 M | |
| Operating Income | 47 M | 49.3 M | |
| Net Income | 18.8 M | 19.7 M | |
| Income Tax Expense | 1.1 M | 1.1 M | |
| Income Before Tax | 19.9 M | 20.9 M | |
| Total Other Income Expense Net | -27.1 M | -28.5 M | |
| Net Income From Continuing Ops | 13.4 M | 14.1 M | |
| Non Operating Income Net Other | 770.5 K | 809 K | |
| Net Loss | -44.6 M | -42.3 M | |
| Interest Income | 14.9 M | 13.7 M | |
| Net Interest Income | -28.7 M | -27.3 M | |
| Change To Netincome | 288.9 K | 274.5 K | |
| Net Income Per Share | 1.04 | 1.10 | |
| Income Quality | 6.33 | 6.65 | |
| Net Income Per E B T | 0.94 | 0.50 |
ANI Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ANI Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ANI Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ANI Pharmaceuticals' important profitability drivers and their relationship over time.
Use ANI Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.ANI Pharmaceuticals Pair Trading
ANI Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ANI Pharmaceuticals position
In addition to having ANI Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sector ETFs Thematic Idea Now
Sector ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sector ETFs theme has 439 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sector ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.